Endologix's CEO Presents At Stephens Inc. Fall Investment Conference - Conference Call Transcript

Endologix, Inc. ( ELGX)

Stephens Inc. Fall Investment Conference

November 15, 2011 11:30 AM ET

Executives

John McDermott – President and CEO

Presentation

Unidentified Analyst

Good morning everyone. Thank you for joining us in the courtesy (ph) for our next presentation we’re honored to have John McDermott, the President and Chief Executive Officer of Endologix with us here today. Endologix is one of our top techs in a Medtech’s face. We have the stock rate overweight with a $14 price target. And you’re going to find that this is definitely the most prolific growth portfolios in the interventional space today and clearly, one of the top 10 growers in Medtech across our 100 plus company universe.

So, with that, I’ll turn it over to John.

John McDermott

Thanks Chris, good morning. John McDermott, I’m the CEO of Endologix. And I’ll take you through our company here. These are our Safe Harbor Statements.

Just briefly executive summary, this is a fast growing medical technology company located in Irvine California. We repair abdominal aortic aneurysms with a very differentiated technology and have a promising pipeline, and I’ll take you through all those details.

The company has also grown nicely. We just reported our third quarter revenue growth of 25%, better than 33% in the US and we’ll go through these markets and the technologies here in detail.

So, this illustrates what we do. The traditional way to repair an aneurysm is the picture on the right, open surgical repair where you get an open abdominal incision from just below your sternum down below your belly button. Your aorta lay is very deep in your torso, it actually is almost laying on your backbone when you lay down. So, it’s a difficult, very invasive procedure.

The newer approaching to repairing these aneurysms is on the illustrations on the left. It’s a catheter based therapy, where through a catheter we have a device that basically realigns the inside, the aorta from the inside out. And basically what we want to do is take the blood flow off of that aneurysm and prevent it from a rupture and now we can do that through a catheter based therapy.

In the United States, about 60% of the EVAR procedures are now done catheter based like you see on the left whereas 40% open repair. And I’ll talk to you about the limitations with EVAR today and how that’s likely to change in the years ahead.

This is the current market for Endovascular grafts, what we call intra-renal or devices below the renal arteries. The importance of that, I’ll make more clear as we go through this. It’s a $1 billion market. Different growth rates in different market segments in the US, it’s growing 6% to 8% in Europe, closer to 5% to 6% in the outside. And the other more emerging markets closer to 10% to 12%.

Blended growth rate of around 8% globally, that’s procedure growth, you can see the average selling prices. These are expensive devices. We have a rep for a clinical specialist in every procedure, so it’s a high touch clinically sophisticated type of an implant. Primary physician that does these is vascular surgeons, also some interventional cardiologists and some cardiac and cardiovascular physicians as well.

This is the competitive landscape, what’s unique about these devices is the evolution, really all of the devices over on the right, the three proximal fixation that was kind of the earlier, the first generation devices. They are grafts with stents basically stone to them. They are implanted through a catheter and deployed and then at the top, there are I don’t have a pointer, but there is, hooks or barbs that attach and anchor into the vessel valve. And that’s what holds the device in place, just below the renal arteries which you can see coming off of this middle picture with Medtronic.

So, these stents that you see right here, they attach and then, the limbs are added to the device from the bottom. So, it’s a top down type of a device. The limitation with that type of an approach is if you lose your purchase and the aortic neck and you slip, then the device is no longer excluding the aneurysm and that’s a type (ph) mode we call a migration.

You can also get Endoleaks in this aneurysm picture you see here in the center. Sometimes you can get leaks from the top, sometimes from the bottom and actually even from the sides or side branches. So, you could effectively exclude an aneurysm but still get an Endoleak and I’ll talk about how we address that later.

Our device is the furnished (ph) over on the left and you can see it’s very different. And instead of using hooks and barbs to attach ourselves into the aortic valve, we actually set the device right on that saddle, where the aorta splits off and goes down into your legs that’s our fixation. So, we don’t fix mechanically per say, but we actually set and using the patients on anatomy. And of course there is nowhere for the device to go. So, migration is not a failure mode with this device.

Early on, yet that being a very intuitive approach obviously, the device has always go very clinical – good clinical results which I’ll show you in a minute. But it was a more difficult system to use. So, early in the company’s evolution, it had a limited range of sizes in a more cumbersome delivery system and that’s what we’ve really worked on over the last few years. Made the device a lot easier to use, built out the range or sizes, so it’s no longer kind of a hard to use niche product. Now it’s just as easy to use as the other devices and to treat a wide range of patients.

Read the rest of this transcript for free on seekingalpha.com

More from Stocks

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

Novo Nordisk Stock Rises 4% Over 2 Sessions

Novo Nordisk Stock Rises 4% Over 2 Sessions

Stock Market Just Took Another Beating -- Here's What You Need to Know

Stock Market Just Took Another Beating -- Here's What You Need to Know

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

Daimler's Profit Warning Should Terrify Traders Before Earnings Season Begins

Daimler's Profit Warning Should Terrify Traders Before Earnings Season Begins